Pharsight

Onureg patents expiration

ONUREG's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11571436 BRISTOL NA
May, 2029

(5 years from now)

Onureg is owned by Bristol.

Onureg contains Azacitidine.

Onureg has a total of 1 drug patent out of which 0 drug patents have expired.

Onureg was authorised for market use on 01 September, 2020.

Onureg is available in tablet;oral dosage forms.

The generics of Onureg are possible to be released after 14 May, 2029.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 1, 2027

Drugs and Companies using AZACITIDINE ingredient

Market Authorisation Date: 01 September, 2020

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ONUREG before it's drug patent expiration?
More Information on Dosage

ONUREG family patents

Family Patents
ONUREG's oppositions filed in EPO
ONUREG Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846628 CELGENE CORP Oral formulations of cytidine analogs and methods of use thereof
Jun, 2030

(6 years from now)

Onureg is owned by Celgene Corp.

Onureg contains Azacitidine.

Onureg has a total of 1 drug patent out of which 0 drug patents have expired.

Onureg was authorised for market use on 01 September, 2020.

Onureg is available in tablet;oral dosage forms.

Onureg can be used as continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy.

The generics of Onureg are possible to be released after 03 June, 2030.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 1, 2027

Drugs and Companies using AZACITIDINE ingredient

Market Authorisation Date: 01 September, 2020

Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not a...

Dosage: TABLET;ORAL

How can I launch a generic of ONUREG before it's drug patent expiration?
More Information on Dosage

ONUREG family patents

Family Patents